View Author
virus vaccine infection fluenza influenza animal response vaccination antibody fluenza virus vaccinia immunization immunity mva-ha-vn vaccinia virus ankara strain vector mva-ha-vn /04 antigen /04 influenza virus group titer pandemic ankara challenge control development candidate macaque protein antibody responses vaccinated protection replication iscom virol challenge infection study virus replication wtmva fluenza viruses model van amerongen g production sutter induction rimmelzwaan /h viruses h 5n viruses assay heterologou expression preparation osterhau influenza viruses /vietnam clade disease plasma number human virus titers kreijtz sutter g evaluation weight safety result immunogenicity weight loss 0/6 h 5n subtype ctl responses cytotoxic mva-ha-ca body temperature 108 pfu iscom ™ mva-ha-ca /09
10 Most Recent Publications
|
Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA
(Article)
Rimmelzwaan, G.F. Kreijtz, J.H.C.M. Suezer, Y. Schwantes, A. Osterhaus, A.D.M.E. Sutter, G. |
2011-10-06
|
|
Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model
(Article)
Kreijtz, J.H.C.M. Süzer, Y. Fouchier, R.A.M. Osterhaus, A.D.M.E. Sutter, G. Rimmelzwaan, G.F. Bodewes, R. Schwantes, A. Amerongen, G. van Verburgh, R.J. Mutsert, G. de Brand, J. van den Trierum, S.E. Kuiken, T. |
2010-11-01
|
|
MVA-based H5N1 vaccine affords cross-clade protection in mice against influenz a A/H5N1 viruses at low doses and after single immunization
(Article)
Kreijtz, J.H.C.M. Suezer, Y. Rimmelzwaan, G.F. Mutsert, G. de Amerongen, G. van Scwantes, A. Brand, J.M.A. van den Fouchier, R.A.M. Löwer, J. Osterhaus, A.D.M.E. Sutter, G. |
2009-11-12
|
|
Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses
(Article)
Kreijtz, J.H.C.M. Suezer, Y. Sutter, G. Rimmelzwaan, G.F. Mutsert, G. de Brand, J.M.A. van den Amerongen, G. van Schnierle, B.S. Kuiken, T. Fouchier, R.A.M. Löwer, J. Osterhaus, A.D.M.E. |
2009-10-23
|
|
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara
(Article)
Rimmelzwaan, G.F. Sutter, G. |
2009-04-01
|
|
Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques
(Article)
Kreijtz, J.H.C.M. Suezer, Y. Sutter, G. Rimmelzwaan, G.F. Mutsert, G. de Brand, J.M.A. van den Amerongen, G. van Schnierle, B.S. Kuiken, T. Fouchier, R.A.M. Löwer, J. Osterhaus, A.D.M.E. |
2009-02-01
|
|
Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA
(Article)
Huisman, W. Schrauwen, E.J. Tijhaar, E.J. Süzer, Y. Pas, S.D. Amerongen, G. van Sutter, G. Rimmelzwaan, G.F. Osterhaus, A.D.M.E. |
2008-12-15
|
|
Recombinant modified vaccinia virus ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1
(Article)
Kreijtz, J.H.C.M. Suezer, Y. Sutter, G. Rimmelzwaan, G.F. Amerongen, G. van Mutsert, G. de Schnierle, B.S. Wood, J.M. Kuiken, T. Fouchier, R.A.M. Löwer, J. Osterhaus, A.D.M.E. |
2007-06-01
|
|
T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells
(Article)
Waal, L. de Süzer, Y. Wyatt, L.S. Sintnicolaas, K. Sutter, G. Moss, B. Osterhaus, A.D.M.E. Swart, R.L. de |
2006-12-01
|
|
Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.
(Article)
Stittelaar, K.J. Gruters, R.A. Schutten, M. Baalen, C.A. van Amerongen, G. van Cranage, M.P. Liljeström, P. Sutter, G. Osterhaus, A.D.M.E. |
2002-07-26
|
